Bain Capital Life Sciences Investors’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-213,908
| Closed | -$1.55M | – | 33 |
|
|
2023
Q1 | $1.55M | Hold |
213,908
| – | – | 0.19% | 32 |
|
|
2022
Q4 | $2.41M | Hold |
213,908
| – | – | 0.27% | 32 |
|
|
2022
Q3 | $2.81M | Hold |
213,908
| – | – | 0.34% | 33 |
|
|
2022
Q2 | $2.7M | Buy |
213,908
+100,000
| +88% | +$1.26M | 0.32% | 35 |
|
|
2022
Q1 | $6.55M | Hold |
113,908
| – | – | 0.64% | 27 |
|
|
2021
Q4 | $13.5M | Hold |
113,908
| – | – | 1.07% | 22 |
|
|
2021
Q3 | $22.6M | Buy |
113,908
+5,908
| +5% | +$1.17M | 1.4% | 17 |
|
|
2021
Q2 | $18.8M | Hold |
108,000
| – | – | 1.23% | 19 |
|
|
2021
Q1 | $21.4M | Hold |
108,000
| – | – | 1.21% | 17 |
|
|
2020
Q4 | $21.2M | Hold |
108,000
| – | – | 1.33% | 15 |
|
|
2020
Q3 | $19.1M | Hold |
108,000
| – | – | 1.78% | 13 |
|
|
2020
Q2 | $25M | Buy |
+108,000
| New | +$25M | 2.62% | 8 |
|